Author pages are created from data sourced from our academic publisher partnerships and public sources.
Regulation of the alpha-galactosidase activity in Streptococcus pneumoniae: characterization of the raffinose utilization system.
A 10.2-kb gene region was identified in the Streptococcus pneumoniae genome sequence that contains eight genes involved in regulation and metabolism of raffinose. The genes rafR and rafS are… Expand
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
- A. Jimeno, J. Li, +6 authors R. Donehower
- Journal of clinical oncology : official journal…
- 1 December 2008
PURPOSE We conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities (DLTs), characterize the pharmacokinetic profile, and document any antitumor activity of… Expand
Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD® in mice
- S. Ghosh, S. Kulkarni, +7 authors K. S. Kumar
- Biology, Medicine
- Journal of radiation research
- 6 June 2012
The aim of the present study was to assess recovery from hematopoietic and gastrointestinal damage by Ex-RAD®, also known as ON01210.Na (4-carboxystyryl-4-chlorobenzylsulfone, sodium salt), after… Expand
Resistance of Streptococcus pneumoniaeto Deformylase Inhibitors Is Due to Mutations indefB
- P. Margolis, C. Hackbarth, +5 authors J. Trias
- Medicine, Biology
- Antimicrobial Agents and Chemotherapy
- 1 September 2001
ABSTRACT Resistance to peptide deformylase inhibitors in Escherichia coli or Staphylococcus aureus is due to inactivation of transformylase activity. Knockout experiments in Streptococcus pneumoniae… Expand
Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response
BackgroundIonizing radiation-induced hematopoietic injury could occur either due to accidental exposure or due to diagnostic and therapeutic interventions. Currently there is no approved drug to… Expand
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Rigosertib (ON 01910.Na) is an inhibitor of the phosphoinositide 3‐kinase and polo‐like kinase pathways that induces mitotic arrest and apoptosis in neoplastic cells, while sparing normal cells. Our… Expand
Radioprotective effects of ON 01210.Na upon oral administration.
ON 01210.Na (Ex-RAD), a chlorobenzylsulfone derivative was investigated for its pharmacologic and radioprotective properties when administered via oral and subcutaneous (SC) routes. The goals of the… Expand
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
BACKGROUND We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic… Expand
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
The multi‐kinase inhibitor rigosertib (ON 01910.Na) induces mitotic arrest and apoptosis in myeloblasts, while sparing normal cells. The purpose of this study was to determine the pharmacokinetic… Expand
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Purpose: Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor activity when combined in… Expand